{"entity":{"id":"nct06054555","kind":"trial","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","aka":[],"tldr":"A phase 3 trial of Nivolumab in melanoma, run by Amgen, active and no longer recruiting.","summary":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma is a phase 3 interventional study registered as NCT06054555 by Amgen, with 633 participants enrolled, started 2023-11-02 and due to reach its primary completion in 2028-01-25. Interventions recorded: ABP 206, Nivolumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06054555","url":"https://clinicaltrials.gov/study/NCT06054555"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06054555","phase":"3","setting":"A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma","sponsor":"Amgen","participation":[{"nct":"NCT06054555","source":"https://clinicaltrials.gov/study/NCT06054555","fetchedAt":"2026-10-07T16:54:09.016Z","studySha256":"35472812b01c0676babf116791e3cebca2556e4aa010f375c884cc988ce0d051","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-12","leadSponsor":"Amgen","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":633,"enrolmentType":"ACTUAL","siteCount":180,"recruitingSiteCount":0,"countries":["Argentina","Bosnia and Herzegovina","Canada","Chile","Croatia","Czechia","Estonia","France","Georgia","Germany","Italy","Jordan","Lebanon","Lithuania","Malaysia","Mexico","Moldova","Netherlands","Philippines","Portugal","Romania","Serbia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United States","Vietnam"]}],"started":"2023-11-02","startedType":"actual","enrolled":633,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06054555/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}